Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Castle Biosciences Inc
(NQ:
CSTL
)
28.88
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Castle Biosciences Inc
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Guardant Health Stock Sees RS Rating Jump To 83
November 20, 2024
On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83.
Via
Investor's Business Daily
Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference
November 20, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year
November 19, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting
November 08, 2024
From
Castle Biosciences, Inc.
Via
Business Wire
The Analyst Landscape: 4 Takes On Castle Biosciences
October 29, 2024
Via
Benzinga
Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett’s Esophagus Test
November 07, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Use of Castle Biosciences’ DecisionDx®-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures, Latest Findings from Prospective, Multicenter DECIDE Study Presented at Dermato-Onco2024
November 06, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences Reports Third Quarter 2024 Results
November 04, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Sotera Health Stock Earns 91 RS Rating
September 10, 2024
On Tuesday, Sotera Health stock hit a key technical milestone, with its Relative Strength Rating climbing to 91, up from 86 the day before.
Via
Investor's Business Daily
Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher® Test to Significantly Reduce Healthcare Costs Associated with the Management of Barrett’s Esophagus Patients
October 29, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Momentum Has Narrowed Again, Significantly
October 28, 2024
It is more of a stock pickers market than usual as momentum factors are currently exaggerated.
Via
Talk Markets
Castle Biosciences to Participate in Upcoming Investor Conferences
October 28, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx®-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b Tumors
October 20, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Recent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain Malignant Potential
October 16, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences to Release Third Quarter 2024 Financial Results and Host Conference Call on Monday, Nov. 4, 2024
October 14, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences to Support the 71st Annual Montagna Symposium on the Biology of the Skin
October 11, 2024
From
Castle Biosciences Inc.
Via
Business Wire
New Prospective, Multicenter Study Presented at SMR Demonstrates Castle Biosciences’ DecisionDx®-Melanoma Test Provides Significant Risk Prediction for Patients with Cutaneous Melanoma, Adding Value to Current Stage-Based Treatment Pathway Decisions
October 09, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences Hosts Groundbreaking Ceremony at Site of New Corporate Headquarters in Friendswood, Texas
October 02, 2024
From
Castle Biosciences Inc.
Via
Business Wire
New Data at ASTRO 2024 Shows Castle Biosciences’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma
September 27, 2024
From
Castle Biosciences Inc.
Via
Business Wire
New Data at AFS 2024 Demonstrates the Strength of Castle Biosciences’ TissueCypher® Test in Independently Predicting Risk of Developing Esophageal Cancer, Guiding Risk-Aligned Management Decisions for Patients with Barrett’s Esophagus
September 23, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Named Arizona Bioscience Leader of the Year
September 16, 2024
From
Castle Biosciences Inc.
Via
Business Wire
DecisionDx®-Melanoma Can Identify Melanoma Patients with Low Risk of Sentinel Lymph Node Positivity Who May Safely Forego Biopsy Surgery, New Independent Study Affirms
September 11, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Study Confirms the Ability of Castle Biosciences' DecisionDx®-SCC Test to Predict Likelihood of Benefit from Adjuvant Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma
September 05, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences to Participate in Upcoming Investor Conferences
August 28, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Yum China Posts Upbeat Earnings, Joins Clear Secure, TG Therapeutics, Bioventus And Other Big Stocks Moving Higher On Tuesday
August 06, 2024
Via
Benzinga
CSTL Stock Earnings: Castle Biosciences Beats EPS, Beats Revenue for Q2 2024
August 05, 2024
CSTL stock results show that Castle Biosciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Castle Biosciences Reports Second Quarter 2024 Results
August 05, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Castle Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference
July 30, 2024
From
Castle Biosciences Inc.
Via
Business Wire
ON Semiconductor Posts Upbeat Earnings, Joins Oil States International, CommScope Holding And Other Big Stocks Moving Higher On Monday
July 29, 2024
Via
Benzinga
Castle Biosciences and Skin Cancer Survivor Teddi Mellencamp Arroyave Launch Campaign to Increase Awareness of Melanoma
July 22, 2024
From
Castle Biosciences Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.